Psychoactive Drug Market: Global Industry Analysis and Forecast

Psychoactive Drug Market Size by Type, Application, End-User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2032

15.2%

CAGR (2025-2032)

5.64 USD Bn.

Market Size

302

Report Pages

145

Market Tables

Overview

The Psychoactive Drug Market size was valued at USD 5.64 Billion in 2024 and the total Psychoactive Drug revenue is expected to grow at a CAGR of 15.2% from 2025 to 2032, reaching nearly USD 17.50 Billion.

Psychoactive Drug Market Overview:

A psychoactive drug, also known as a psychoactive substance, or neuropsychiatric medication, is a chemical compound that alters the function of the nervous system, resulting in changes in perspective, emotion, awareness, reasoning, or behavior. These chemicals can be used for therapeutic reasons, leisure purposes, to boost efficiency or modify cognition, as psychedelics for ceremonial, mystical purposes, or study. Doctors and other healthcare providers recommend some types of psychoactive medications that have clinical benefits.

To know about the Research Methodology :- Request Free Sample Report

Psychoactive chemicals frequently cause perceived (albeit objectively seen) alterations in cognition and demeanor that the individual may feel gratifying and pleasurable (exhilaration or a sensation of calm) or beneficial in a directly observable or measured way. Medications that are gratifying and hence possess positive reinforcement properties can develop addictive behavior even in the wake of negative consequences.

In this report, the Psychoactive Drug market's growth reasons, as well as the market's many segments (Type, Application, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Psychoactive Drug market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Psychoactive Drug market situation.

Psychoactive Drug Market Dynamics:

The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market. Humans utilize psychoactive chemicals for a variety of objectives to attain a certain goal. These applications differ greatly between civilizations. Some chemicals may be used for regulated or illicit reasons, while others may be used for ceremonial objectives, and yet others may be used for healing properties. Alcohol dependence, serotonergic drugs, and sleeping tablets are some examples. Caffeine is the most extensively used psychoactive stimulant in the world, yet unlike others, it is permitted and uncontrolled in almost all governments.

The risks related to general anesthesia are one of the major restraints of the market. The use of antihypertensive medications, particularly general anesthetic medicines, in pediatric patients necessitates extra caution. Infants and toddlers react in different ways to anesthetic medicines than adults owing to a variety of characteristics such as bone density, enzyme production, skin temperature, pulse rate distribution, and structural development of the kidney and liver.

The COVID-19 outbreak has had a substantial impact on the market for Psychoactive Drugs. The general anesthetic medicines business is facing production and supply chain problems, such as timely delivery of products to end customers and dealing with fluctuating product demand. The psychoactive drug industry is seeing short-term slower growth. It can be ascribed to causes. e.g. a reduction in sales volume from key consumers, restricted procedures in most clinics, interrupted distribution network, and difficulties in offering valuable services as a result of shutdowns.

Psychoactive Drug Market Segment Analysis:

By Type, the Cannabis segment is expected to grow at a CAGR of 9.3% in the previously mentioned forecast period. Cannabis legalization is frequently seen with mixed feelings, as it is received with mistrust due to the possibility of exploitation. Cannabis legalization has helped individuals to practice safe drug use while also discovering its medical advantages. As a result, numerous governments throughout the world are increasingly legalizing cannabis use. While most nations throughout the world have yet to legalize recreational marijuana use, attitudes about consumption and sales have shifted over time. This has resulted in an increase in the prominence of cannabis use in many countries, fueling the growth in the global cannabis segment of the psychoactive drug market.

Medical cannabis makes for a sizable portion of the psychoactive drug industry. Many nations, including Australia, Chile, Germany, Israel, the Netherlands, Poland, Portugal, and Uruguay, have allowed the medical use of cannabis. Consumers in cannabis-legalized states in the United States are primarily above the age of 45. These demographic characteristics are predicted to promote cannabis demand in the country due to the increased likelihood of chronic illnesses after the age of 45 and the efficacy of cannabis on such disorders.

Regional Insights:

The market for psychoactive pharmaceuticals is dominated by the North American continent. Increased knowledge of psychological illnesses e.g. depression and anxiety in North America is predicted to drive the advancement of the psychoactive drug industry. Financial hardship, the division of family-oriented structural supports, and worsening ecological factors are also expected to drive market growth over the projection period.

In 2020, 63 million people were estimated to have used opioids i.e., opiates and pharmaceutical and synthetic opioids for non-medical reasons at the global level. This corresponds to nearly 1.3% of the global population aged 14–65. The places with the highest past-year prevalence of use of opioids were North America (3.7%) and the Middle East along with South-West Asia (3.3%) and Oceania (2.7%, especially Australia and New Zealand). In Asia, although the prevalence of last year’s opioid use is at a comparable level to the global average, more than half (55%) of the estimated global number of opioid users lie in that part of the world.

Despite the lack of worldwide data, the non-medical use of prescription opioids is described as a serious issue in several countries, including West and North Africa, the Near and Middle East (primarily tramadol), and North America (hydrocodone, codeine, tramadol, and fentanyl). In Western and Central Europe, there are also indicators of increased non-medical use of prescription opioids, as evidenced by an increase in the percentage of referrals to therapy for this use.

The objective of the report is to present a comprehensive analysis of the Psychoactive Drug market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Psychoactive Drug market dynamics, structure by analyzing the market segments and projecting the Psychoactive Drug market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Psychoactive Drug market make the report investor’s guide.

Psychoactive Drug Market Scope: Inquire before buying

Psychoactive Drug Market
Report Coverage	Details
Base Year:	2024	Forecast Period:	2025-2032
Historical Data:	2019 to 2024	Market Size in 2024:	USD 5.64 Bn.
Forecast Period 2025 to 2032 CAGR:	15.2%	Market Size in 2032:	USD 17.50 Bn.
Segments Covered:	by Type	Diphenhydramine (Benadryl) Amanita muscaria mushroom Tylenol 3 (contains codeine) Codeine Pipe tobacco Bupropion (Zyban) Cannabis Hashish Other
	by Application	Anesthesia Pain management Mental disorders Recreation Ritual and spiritual Military Other
	by End-User	Hospitals Homecare Specialty Clinics Other

Psychoactive Drug Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Psychoactive Drug Market, Key Players

1. Abbott Laboratories
2. Sanofi S.A.
3. Cipla Limited
4. Biocon Limited
5. Intas Pharmaceuticals Ltd.
6. Sun Pharmaceutical Industries Ltd.
7. Cadila Pharmaceuticals
8. Lupin Limited
9. Emcure Pharmaceuticals Ltd.
10. Novartis International AG
11. Dr. Reddy’s Laboratories Limited
12. Alkem Laboratories Limited
13. The Emmes Company
14. Klarisana
15. AstraZeneca
16. F. Hoffmann-La Roche Ltd

FAQs:

1. Which is the potential market for the Psychoactive Drug in terms of the region?
Ans. The market for psychoactive pharmaceuticals is dominated by the North American continent

2. What are the opportunities for new market entrants?
Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market.

3. What is expected to drive the growth of the Psychoactive Drug market in the forecast period?
Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market.

4. What is the projected market size & growth rate of the Psychoactive Drug Market?
Ans. The Psychoactive Drug Market size was valued at USD 5.64 Billion in 2024 and the total Psychoactive Drug revenue is expected to grow at a CAGR of 15.2% from 2025 to 2032, reaching nearly USD 17.50 Billion.

5. What segments are covered in the Psychoactive Drug Market report?
Ans. The segments covered are Type, Application, End-User, and Region.

1. Psychoactive Drug Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Psychoactive Drug Market: Dynamics 2.1. Psychoactive Drug Market Trends by Region 2.1.1. North America Psychoactive Drug Market Trends 2.1.2. Europe Psychoactive Drug Market Trends 2.1.3. Asia Pacific Psychoactive Drug Market Trends 2.1.4. Middle East and Africa Psychoactive Drug Market Trends 2.1.5. South America Psychoactive Drug Market Trends 2.2. Psychoactive Drug Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Psychoactive Drug Market Drivers 2.2.1.2. North America Psychoactive Drug Market Restraints 2.2.1.3. North America Psychoactive Drug Market Opportunities 2.2.1.4. North America Psychoactive Drug Market Challenges 2.2.2. Europe 2.2.2.1. Europe Psychoactive Drug Market Drivers 2.2.2.2. Europe Psychoactive Drug Market Restraints 2.2.2.3. Europe Psychoactive Drug Market Opportunities 2.2.2.4. Europe Psychoactive Drug Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Psychoactive Drug Market Drivers 2.2.3.2. Asia Pacific Psychoactive Drug Market Restraints 2.2.3.3. Asia Pacific Psychoactive Drug Market Opportunities 2.2.3.4. Asia Pacific Psychoactive Drug Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Psychoactive Drug Market Drivers 2.2.4.2. Middle East and Africa Psychoactive Drug Market Restraints 2.2.4.3. Middle East and Africa Psychoactive Drug Market Opportunities 2.2.4.4. Middle East and Africa Psychoactive Drug Market Challenges 2.2.5. South America 2.2.5.1. South America Psychoactive Drug Market Drivers 2.2.5.2. South America Psychoactive Drug Market Restraints 2.2.5.3. South America Psychoactive Drug Market Opportunities 2.2.5.4. South America Psychoactive Drug Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Psychoactive Drug Industry 2.8. Analysis of Government Schemes and Initiatives For Psychoactive Drug Industry 2.9. Psychoactive Drug Market Trade Analysis 2.10. The Global Pandemic Impact on Psychoactive Drug Market 3. Psychoactive Drug Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2024-2032 3.1. Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 3.1.1. Diphenhydramine (Benadryl) 3.1.2. Amanita muscaria mushroom 3.1.3. Tylenol 3 (contains codeine) 3.1.4. Codeine 3.1.5. Pipe tobacco 3.1.6. Bupropion (Zyban) 3.1.7. Cannabis 3.1.8. Hashish 3.1.9. Other 3.2. Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 3.2.1. Anesthesia 3.2.2. Pain management 3.2.3. Mental disorders 3.2.4. Recreation 3.2.5. Ritual and spiritual 3.2.6. Military 3.2.7. Other 3.3. Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 3.3.1. Hospitals 3.3.2. Homecare 3.3.3. Specialty Clinics 3.3.4. Other 3.4. Psychoactive Drug Market Size and Forecast, by Region (2024-2032) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Psychoactive Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 4.1. North America Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 4.1.1. Diphenhydramine (Benadryl) 4.1.2. Amanita muscaria mushroom 4.1.3. Tylenol 3 (contains codeine) 4.1.4. Codeine 4.1.5. Pipe tobacco 4.1.6. Bupropion (Zyban) 4.1.7. Cannabis 4.1.8. Hashish 4.1.9. Other 4.2. North America Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 4.2.1. Anesthesia 4.2.2. Pain management 4.2.3. Mental disorders 4.2.4. Recreation 4.2.5. Ritual and spiritual 4.2.6. Military 4.2.7. Other 4.3. North America Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 4.3.1. Hospitals 4.3.2. Homecare 4.3.3. Specialty Clinics 4.3.4. Other 4.4. North America Psychoactive Drug Market Size and Forecast, by Country (2024-2032) 4.4.1. United States 4.4.1.1. United States Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 4.4.1.1.1. Diphenhydramine (Benadryl) 4.4.1.1.2. Amanita muscaria mushroom 4.4.1.1.3. Tylenol 3 (contains codeine) 4.4.1.1.4. Codeine 4.4.1.1.5. Pipe tobacco 4.4.1.1.6. Bupropion (Zyban) 4.4.1.1.7. Cannabis 4.4.1.1.8. Hashish 4.4.1.1.9. Other 4.4.1.2. United States Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 4.4.1.2.1. Anesthesia 4.4.1.2.2. Pain management 4.4.1.2.3. Mental disorders 4.4.1.2.4. Recreation 4.4.1.2.5. Ritual and spiritual 4.4.1.2.6. Military 4.4.1.2.7. Other 4.4.1.3. United States Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 4.4.1.3.1. Hospitals 4.4.1.3.2. Homecare 4.4.1.3.3. Specialty Clinics 4.4.1.3.4. Other 4.4.2. Canada 4.4.2.1. Canada Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 4.4.2.1.1. Diphenhydramine (Benadryl) 4.4.2.1.2. Amanita muscaria mushroom 4.4.2.1.3. Tylenol 3 (contains codeine) 4.4.2.1.4. Codeine 4.4.2.1.5. Pipe tobacco 4.4.2.1.6. Bupropion (Zyban) 4.4.2.1.7. Cannabis 4.4.2.1.8. Hashish 4.4.2.1.9. Other 4.4.2.2. Canada Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 4.4.2.2.1. Anesthesia 4.4.2.2.2. Pain management 4.4.2.2.3. Mental disorders 4.4.2.2.4. Recreation 4.4.2.2.5. Ritual and spiritual 4.4.2.2.6. Military 4.4.2.2.7. Other 4.4.2.3. Canada Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 4.4.2.3.1. Hospitals 4.4.2.3.2. Homecare 4.4.2.3.3. Specialty Clinics 4.4.2.3.4. Other 4.4.3. Mexico 4.4.3.1. Mexico Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 4.4.3.1.1. Diphenhydramine (Benadryl) 4.4.3.1.2. Amanita muscaria mushroom 4.4.3.1.3. Tylenol 3 (contains codeine) 4.4.3.1.4. Codeine 4.4.3.1.5. Pipe tobacco 4.4.3.1.6. Bupropion (Zyban) 4.4.3.1.7. Cannabis 4.4.3.1.8. Hashish 4.4.3.1.9. Other 4.4.3.2. Mexico Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 4.4.3.2.1. Anesthesia 4.4.3.2.2. Pain management 4.4.3.2.3. Mental disorders 4.4.3.2.4. Recreation 4.4.3.2.5. Ritual and spiritual 4.4.3.2.6. Military 4.4.3.2.7. Other 4.4.3.3. Mexico Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 4.4.3.3.1. Hospitals 4.4.3.3.2. Homecare 4.4.3.3.3. Specialty Clinics 4.4.3.3.4. Other 5. Europe Psychoactive Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 5.1. Europe Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.2. Europe Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.3. Europe Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 5.4. Europe Psychoactive Drug Market Size and Forecast, by Country (2024-2032) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.1.2. United Kingdom Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.1.3. United Kingdom Psychoactive Drug Market Size and Forecast, by End-User(2024-2032) 5.4.2. France 5.4.2.1. France Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.2.2. France Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.2.3. France Psychoactive Drug Market Size and Forecast, by End-User(2024-2032) 5.4.3. Germany 5.4.3.1. Germany Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.3.2. Germany Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.3.3. Germany Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 5.4.4. Italy 5.4.4.1. Italy Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.4.2. Italy Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.4.3. Italy Psychoactive Drug Market Size and Forecast, by End-User(2024-2032) 5.4.5. Spain 5.4.5.1. Spain Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.5.2. Spain Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.5.3. Spain Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 5.4.6. Sweden 5.4.6.1. Sweden Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.6.2. Sweden Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.6.3. Sweden Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 5.4.7. Austria 5.4.7.1. Austria Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.7.2. Austria Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.7.3. Austria Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 5.4.8.2. Rest of Europe Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 5.4.8.3. Rest of Europe Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6. Asia Pacific Psychoactive Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 6.1. Asia Pacific Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.2. Asia Pacific Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.3. Asia Pacific Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4. Asia Pacific Psychoactive Drug Market Size and Forecast, by Country (2024-2032) 6.4.1. China 6.4.1.1. China Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.1.2. China Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.1.3. China Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.2. S Korea 6.4.2.1. S Korea Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.2.2. S Korea Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.2.3. S Korea Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.3. Japan 6.4.3.1. Japan Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.3.2. Japan Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.3.3. Japan Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.4. India 6.4.4.1. India Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.4.2. India Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.4.3. India Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.5. Australia 6.4.5.1. Australia Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.5.2. Australia Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.5.3. Australia Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.6. Indonesia 6.4.6.1. Indonesia Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.6.2. Indonesia Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.6.3. Indonesia Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.7. Malaysia 6.4.7.1. Malaysia Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.7.2. Malaysia Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.7.3. Malaysia Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.8. Vietnam 6.4.8.1. Vietnam Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.8.2. Vietnam Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.8.3. Vietnam Psychoactive Drug Market Size and Forecast, by End-User(2024-2032) 6.4.9. Taiwan 6.4.9.1. Taiwan Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.9.2. Taiwan Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.9.3. Taiwan Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 6.4.10.2. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 6.4.10.3. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 7. Middle East and Africa Psychoactive Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 7.1. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 7.2. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 7.3. Middle East and Africa Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 7.4. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Country (2024-2032) 7.4.1. South Africa 7.4.1.1. South Africa Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 7.4.1.2. South Africa Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 7.4.1.3. South Africa Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 7.4.2. GCC 7.4.2.1. GCC Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 7.4.2.2. GCC Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 7.4.2.3. GCC Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 7.4.3. Nigeria 7.4.3.1. Nigeria Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 7.4.3.2. Nigeria Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 7.4.3.3. Nigeria Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 7.4.4.2. Rest of ME&A Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 7.4.4.3. Rest of ME&A Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 8. South America Psychoactive Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 8.1. South America Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 8.2. South America Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 8.3. South America Psychoactive Drug Market Size and Forecast, by End-User(2024-2032) 8.4. South America Psychoactive Drug Market Size and Forecast, by Country (2024-2032) 8.4.1. Brazil 8.4.1.1. Brazil Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 8.4.1.2. Brazil Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 8.4.1.3. Brazil Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 8.4.2. Argentina 8.4.2.1. Argentina Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 8.4.2.2. Argentina Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 8.4.2.3. Argentina Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Psychoactive Drug Market Size and Forecast, by Type (2024-2032) 8.4.3.2. Rest Of South America Psychoactive Drug Market Size and Forecast, by Application (2024-2032) 8.4.3.3. Rest Of South America Psychoactive Drug Market Size and Forecast, by End-User (2024-2032) 9. Global Psychoactive Drug Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Psychoactive Drug Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Abbott Laboratories 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Sanofi S.A. 10.3. Cipla Limited 10.4. Biocon Limited 10.5. Intas Pharmaceuticals Ltd. 10.6. Sun Pharmaceutical Industries Ltd. 10.7. Cadila Pharmaceuticals 10.8. Lupin Limited 10.9. Emcure Pharmaceuticals Ltd. 10.10. Novartis International AG 10.11. Dr. Reddy’s Laboratories Limited 10.12. Alkem Laboratories Limited 10.13. The Emmes Company 10.14. Klarisana 10.15. AstraZeneca 10.16. F. Hoffmann-La Roche Ltd 11. Key Findings 12. Industry Recommendations 13. Psychoactive Drug Market: Research Methodology 14. Terms and Glossary

Psychoactive Drug Market

Choose License Type